Novita

Interim report: SciBase

Retrieved on: 
Friday, August 18, 2023

Electrode sales volume increased by 17% and was 22,944 (19,580) units.

Key Points: 
  • Electrode sales volume increased by 17% and was 22,944 (19,580) units.
  • Repeat sales of electrodes to existing customers increased by 1%.
  • Overall sales increased by 36% (+24, before currency effects).
  • No events of significant nature have occurred after the end of the period.

Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results

Retrieved on: 
Wednesday, August 9, 2023

Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history

Key Points: 
  • Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history
    PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financial update.
  • Second quarter Net Revenue was $11.0 million, a $3.6 million increase over second quarter 2022.
  • Income from continuing operations in the second quarter of 2023 was $0.4 million, an improvement of $2.5 million from the prior year quarter’s loss of $2.1 million.
  • “As reported in our preliminary Q2 business results published July 10, 2023, the Company achieved record volume, revenue, income and cash collections in Q2”, said Chris McCarthy, Chief Financial Officer.

Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement

Retrieved on: 
Monday, July 10, 2023

Final Q2 financial results are expected to be released no later than August 11, 2023.

Key Points: 
  • Final Q2 financial results are expected to be released no later than August 11, 2023.
  • Second quarter Net Revenue was $11 million, fueled by significant volume growth for ThyGeNEXT® + ThyraMIR®v2 and PancraGEN®.
  • First half revenue was $20.9 million resulting in a 36.1% increase over 2022.
  • As a result, Interpace is able to continue offering PancraGEN and the related Point2® fluid chemistry tests for amylase, CEA, and glucose.

Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023

Retrieved on: 
Monday, June 5, 2023

The important information provided by PancraGEN helps support the differential diagnosis of pancreatic cancer by integrating the results of first-line tests and procedures with molecular test results.

Key Points: 
  • The important information provided by PancraGEN helps support the differential diagnosis of pancreatic cancer by integrating the results of first-line tests and procedures with molecular test results.
  • For the past decade, CMS has provided reimbursement for PancraGEN, and over that time nearly 70,000 patients have been tested on orders from physicians across the country.
  • We are extremely disappointed that CMS, through its Medicare Administrative Contractor (MAC), Novitas, is ending coverage for PancraGEN—an important and widely utilized test.
  • Yet, studies have shown that 60% to 80% of surgeries reveal indolent cysts that did not necessarily require surgery.

Novitas Solutions awarded MAC JL contract

Retrieved on: 
Friday, July 30, 2021

JACKSONVILLE, Fla., July 30, 2021 /PRNewswire/ -- Novitas Solutions, Inc. (Novitas) has been awarded the Jurisdiction L (JL) contract by the Centers for Medicare & Medicaid Services (CMS).

Key Points: 
  • JACKSONVILLE, Fla., July 30, 2021 /PRNewswire/ -- Novitas Solutions, Inc. (Novitas) has been awarded the Jurisdiction L (JL) contract by the Centers for Medicare & Medicaid Services (CMS).
  • "I am extremely pleased that CMS has awarded this contract to Novitas.
  • After a competitive process, CMS awarded Novitas the contract with one-year base period with six one-year options.
  • Novitas also holds the MAC JH contract which serves Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma and Texas.

Novita Pharmaceuticals and China Resources Double Crane Pharmaceutical Enter into an Exclusive License Agreement to Develop and Commercialize Fascin Inhibitor in China

Retrieved on: 
Wednesday, July 28, 2021

CRDC will receive the rights to research, develop, manufacture, and exclusively commercialize Novita's fascin inhibitor in oncology applications in the Greater China region.

Key Points: 
  • CRDC will receive the rights to research, develop, manufacture, and exclusively commercialize Novita's fascin inhibitor in oncology applications in the Greater China region.
  • In addition to excellent safety and pharmacokinetic profiles, NP-G2-044 has shown preliminary and exciting signals of efficacy in late-stage cancer patients.
  • "Novita is delighted to license our first-in-class fascin inhibitor to one of the largest pharmaceutical companies in China," said Jillian Zhang, Ph.D., President and Chief Scientific Officer of Novita.
  • About China Resources Double Crane Pharmaceutical Co., Ltd.
    China Resources Double Crane Pharmaceutical Co., Ltd. ("CRDC"), established in 1939 and headquartered in Beijing, China, has 21 subsidiaries and more than 11,000 employees throughout the country.

Hillrom Comments on Recent Novitas Reimbursement Update

Retrieved on: 
Sunday, April 11, 2021

b'CHICAGO, April 11, 2021 /PRNewswire/ -- Hillrom (NYSE: HRC) previously announced its intent to acquire Bardy Diagnostics, Inc. (BardyDx).

Key Points: 
  • b'CHICAGO, April 11, 2021 /PRNewswire/ -- Hillrom (NYSE: HRC) previously announced its intent to acquire Bardy Diagnostics, Inc. (BardyDx).
  • On April 10, 2021, the Medicare Administrative Contractor (MAC), Novitas Solutions, published updated reimbursement rates applicable to the Current Procedural Terminology (CPT) codes 93241, 93243, 93245 and 93247 for the extended Holter cardiac monitoring category applicable to all of BardyDx\'s products and services.
  • The original Novitas rate decision was published on January 29, 2021.\nFollowing the updated Novitas rate decision, Hillrom reconfirms its position that a "Company Material Adverse Effect" has occurred under the acquisition agreement with BardyDx, and therefore closing conditions have not been satisfied.
  • Hillrom assumes no obligation to update or revise any forward-looking statements, unless required by law.\n'

iRhythm® Technologies Announces Conference Call to Discuss Medicare Administrative Contractor (MAC) Novitas’s Updated Rate Publication

Retrieved on: 
Saturday, April 10, 2021

On April 10, 2021, Novitas published updated reimbursement rates for codes 93243 and 93247 at $103 and $115, respectively.

Key Points: 
  • On April 10, 2021, Novitas published updated reimbursement rates for codes 93243 and 93247 at $103 and $115, respectively.
  • Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the Investors section of the companys website at: www.irhythmtech.com .
  • iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed.
  • The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

iRhythm Technologies Provides Statement on Medicare Administrative Contractor (MAC) Novitas Recent Rate Publication

Retrieved on: 
Friday, January 29, 2021

The Company is seeking additional information from Novitas and will provide updates as soon as practicable.

Key Points: 
  • The Company is seeking additional information from Novitas and will provide updates as soon as practicable.
  • iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed.
  • Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially.
  • iRhythm disclaims any obligation to update these forward-looking statements.

GuideWell Source Announces Leadership Changes

Retrieved on: 
Tuesday, January 29, 2019

Prior to joining GuideWell Source, Dikter held a number of executive positions with Exelon Corporation.

Key Points: 
  • Prior to joining GuideWell Source, Dikter held a number of executive positions with Exelon Corporation.
  • Throughout Harvey's tenure, he's helped our corporate performance reach historic highs, and has been instrumental in developing and driving our customer focused culture throughout the GuideWell Source Family of Companies," Coston said.
  • The company also announced the following additions to its leadership team:
    Karen Hrubiak, vice president of Business Development.
  • Headquartered in Jacksonville, Fla., GuideWell Source is the corporate services and parent company for First Coast Service Options, Inc., Novitas Solutions, Inc. and GuideWell Allegiance, which provide administrative services for government-sponsored healthcare programs.